• Room 02.021 - Pharmacy & MCI Block 98 MBC Site

    United Kingdom

Accepting PhD Students

19962019
If you made any changes in Pure these will be visible here soon.

Personal profile

Research Statement

I hold a Chair in Clinical Pharmacy and am the Director of Research at the School of Pharmacy, Queen’s University Belfast. I have an international track record in lung microbiome research with my translational research programme focusing primarily on the improved detection and treatment of lung infection in patients with respiratory diseases such as cystic fibrosis (CF), non-CF bronchiectasis and COPD.  I have published over 100 research papers in peer-reviewed journals and serves on a number of scientific advisory boards as well as editorial boards.

I lead a multidisciplinary team of research staff including pharmacists, microbiologists and clinicians. My laboratory is a world class centre of excellence which aims to develop the next generation of treatments, diagnostic tools and standards of care in order to alleviate or cure respiratory infection.

All staff and students in my team are dedicated to working together to push the boundaries of scientific and clinical discovery. Our goal is to translate these advances into new clinical and therapeutic approaches that will ultimately improve the lives of patients with cystic fibrosis (CF) and other respiratory diseases.

Research in my group is focused primarily on the improved detection and treatment of lung infection in patients with respiratory diseases such as cystic fibrosis (CF), non-CF bronchiectasis and chronic obstructive pulmonary disease. Microbiome analysis is performed, using both enhanced aerobic and anaerobic culture techniques and non-culture based next- generation sequencing, on samples from patients with CF, bronchiectasis, COPD and primary immune deficiency. Using these techniques, we have identified that a much wider range of bacteria may cause respiratory infection in patients with these diseases than was previously thought. We have also discovered that bacteria which do not require oxygen to live may be present in the airways.

 

My team’s current research programme is designed to:

• Establish the role of these organisms in causing infection and damage in the lungs of patients with respiratory disease

• Determine why these bacteria develop resistance to antibiotics used to treat infection

• Evaluate the efficacy of antibiotics and other agents under low oxygen conditions which mimic conditions in the lung and;

• Examine whether changes in antibiotic treatment to target a wider range of bacteria present in the lungs result in improved clinical outcomes for patients

Our group are also leading a €50 million, 5-year Europe-wide, Innovative Medicines Initiative (IMI) funded project to develop new drugs that could improve the lives of patients with CF and bronchiectasis. The iABC (inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis) consortium, which is made up of industry partners Novartis and Polyphor and world-leading lung specialists from across Europe, will develop new ‘inhaled antibiotics’ to manage chronic lung infection, the main cause of disease and death in patients with these conditions.

Watch more about my research on this video.

Research Statement

Teaching

  •  

 

Achievements

Teaching

Fingerprint Dive into the research topics where Michael Tunney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 47 Similar Profiles
Cystic Fibrosis Medicine & Life Sciences
Lung Medicine & Life Sciences
Pseudomonas aeruginosa Medicine & Life Sciences
Anti-Bacterial Agents Medicine & Life Sciences
Microbiota Medicine & Life Sciences
Biofilms Medicine & Life Sciences
Infection Medicine & Life Sciences
Methicillin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2010 2018

Research Output 1996 2019

A general protein O-glycosylation machinery conserved in Burkholderia species improves bacterial fitness and elicits glycan immunogenicity in humans

Mohamed, Y. F., Scott, N. E., Molinaro, A., Creuzenet, C., Ortega, X., Lertmemongkolchai, G., Tunney, M. M., Green, H., Jones, A. M., DeShazer, D., Currie, B. J., Foster, L. J., Ingram, R., De Castro, C. & Valvano, M. A., 26 Jul 2019, In : The Journal of biological chemistry.

Research output: Contribution to journalArticle

Open Access
File
Burkholderia
Glycosylation
Machinery
Polysaccharides
Burkholderia cenocepacia
1 Citation (Scopus)
Cystic Fibrosis
Sputum
Biota
Microbiota
Logistic Models
1 Citation (Scopus)

Community analysis and co-occurrence patterns in airway microbial communities during health and disease

Einarsson, G. G., Zhao, J., LiPuma, J. J., Downey, D. G., Tunney, M. M. & Elborn, J. S., 08 Jul 2019, In : ERJ Open. 5, 3, 11 p., 00128-2017.

Research output: Contribution to journalArticle

Open Access
File
Microbiota
Health
Bacteria
Chronic Disease
Burkholderia cepacia complex

Composition of the airway bacterial community correlates with chest HRCT in adults with bronchiectasis

O'Neill, K., Einarsson, G., Rowan, S., McIlreavey, L., Lee, A., Lawson, J., Lynch, T., Horsley, A., Bradley, J., Elborn, J. & Tunney, M., 30 Jul 2019, In : Respirology.

Research output: Contribution to journalArticle

Bronchiectasis
Thorax
Tomography
rRNA Genes
Spirometry
Home Care Services
Inappropriate Prescribing
Guideline Adherence
Clostridium
Nursing Homes

Activities 2003 2003

  • 1 Membership of external research organisation

Higher Education Academy (External organisation)

Michael Tunney (Member)
2003 → …

Activity: Membership typesMembership of external research organisation